



## (51) International Patent Classification:

*C07D 413/14* (2006.01) *A61P 31/00* (2006.01)  
*A61K 31/4184* (2006.01)

## (21) International Application Number:

PCT/US2012/021280

## (22) International Filing Date:

13 January 2012 (13.01.2012)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/433,169 14 January 2011 (14.01.2011) US

(71) Applicant (for all designated States except US): **VERTEX PHARMACEUTICALS INCORPORATED** [US/US]; 130 Waverly Street, Cambridge, MA 02139 (US).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): **SHANNON, Dean** [CA/US]; 19 Stonybrook Lane, Milford, MA 01757 (US). **LUISI, Brian** [US/US]; 15 Gibbens Street, Somerville, MA 02143 (US). **KRAWIEC, Mariusz** [PL/US]; 46 Littlefield Lane, Marlborough, MA 01752 (US). **KULDIP-**

**KUMAR, Anuj, K.** [IN/US]; 282 Fellsway West, Medford, MA 02155 (US).

(74) Agent: **BOUDREAUX, William, R.**; Brinks Hofer Gilson & Lione, 524 South Main Street, Suite 200, Ann Arbor, MI 48104 (US).



(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[6-FLUORO-5-[2-(1-HYDROXY-1-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA

FIG. 1



(57) Abstract: The present application is directed to solid forms of compounds of formula (I) and pharmaceutically acceptable salts thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutical compositions comprising said compounds and salts. These compounds and salts are useful in treating bacterial infections.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

— *as to the applicant's entitlement to claim the priority of  
the earlier application (Rule 4.17(iii))*

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii))*

**Published:**

— *with international search report (Art. 21(3))*